Millions of screenings and treatments have been missed resulting in a rise in metastatic cancers. Cancer survivorship has made great strides, with death rates declining 31% since 1991 and oncology clinical trials dominating therapeutic focus. But cancer patients require uninterrupted care, and the full impact on survivorship of disruptions in care caused by the pandemic […]
Read MoreCOVID-19 propels clinical trial innovations from prolonged conjecture to a paradigm shift. Between March and November of 2020, COVID-19 negatively affected more than 1,200 clinical trials worldwide. Some were shut down completely while others were affected by lockdowns, patients becoming reluctant to continue with a trial or a host of other pandemic-related interruptions. As in […]
Read MoreWritten by Maria Ali in collaboration with Suzanna Phelps-Fredette Medical history began with a holistic approach Medical philosophy and practice dates back to the Indian Ayurvedic system of medicine and ancient Greek, Roman and Islamic physicians. Both took a holistic approach that considered the physical, mental and emotional health of a person as well as […]
Read More
Excellent resources, proven experience and financial incentives make APAC a smart choice for First-in-Human and early phase clinical trials. Clinical trials are moving east Challenges to conducting trials in the West, especially recruitment difficulties, have made the APAC region a preferred destination for clinical trials. APAC offers a high availability of patients, worldwide accepted […]
Read More
When clinical trials become a normal part of care options for patients with unmet needs, both researchers and patients will reap exponential rewards. “Where are the patients?” Clinical trials hinge on recruitment, and enrollment issues are a perpetual challenge. Research estimates that, on average, around 20-25% of trials across all phases and therapeutic areas are […]
Read MoreGeorge Clinical teams draw on proven working models, established global relationships and unflinching dedication to implement clinical trial in a matter of weeks. In the dark times of global COVID-19 lockdowns, scientists and healthcare workers pressed forward in their mission of caring for and protecting the sick, particularly those who were contracting COVID-19. The global […]
Read MoreThe following article is written by George Clinical’s CMO, Maria Ali. When outcomes are all that drive us we miss out on many important opportunities. There has been a clear paradigm shift over the last few decades with regard to patients’ role in their medical care and treatment options. The old system whereby a […]
Read MoreGeorge Clinical CMO, Maria Ali, talks with ISN President Vivekanand Jha about renal disease in the developing world. Professor Jha is also the Executive Director at The George Institute for Global Health India, member of the Scientific Leadership Committee at George Clinical and a James Martin Fellow at The George Institute for Global Health, University […]
Read MoreDr. Mikhail Kosiborod is a cardiologist, Vice President of Research at Saint Luke’s Health System, Director of Cardiometabolic Research and the Haverty Cardiometabolic Center of Excellence at Saint Luke’s Mid America Heart Institute, and Professor of Medicine at the University of Missouri-Kansas City. He serves as one of George Clinical’s scientific leaders. Dr. Maria Ali, CMO, […]
Read MoreDr. Maria Ali, CMO, and Meg Jardine, MBBS, Associate Professor at the University of New South Wales and member of the CREDENCE steering committee, discuss the results and implications of the CREDENCE trial. Maria: As a physician, you’ve chosen to focus on research. Why is research like CREDENCE so important for healthcare in general and, […]
Read More
